Digital Mood-enhanced CBT-I to Improve Depressive Symptoms in Adolescents
Launched by CHINESE UNIVERSITY OF HONG KONG · Apr 9, 2024
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to help teenagers who are struggling with both insomnia (trouble sleeping) and depression. The study is comparing two types of online therapy: one that focuses on improving both sleep and mood (called mood-enhanced cognitive behavioral therapy for insomnia, or M-dCBT-I) and a standard version that just focuses on sleep (called dCBT-I). The goal is to see which approach is more effective in reducing depressive symptoms in adolescents and whether the benefits last over time.
To be eligible for this study, participants need to be Chinese adolescents aged 12 to 18 who have significant insomnia and moderate depression as identified by specific questionnaires. They should also be able to read and understand Chinese and own a smartphone. However, those with serious suicidal thoughts or other major mental health disorders, as well as certain sleep disorders, won't be able to participate. If you or someone you know fits the criteria, this study could provide helpful insights into improving both sleep and mood for teenagers facing these challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Chinese adolescent aged 12-18 years old
- • 2. presence of insomnia problems as defined by insomnia severity index ≥ 9 (locally validated cut off for detecting clinical insomnia in adolescents)
- • 3. presence of depressive problems as defined by Patient Health Questionnaire-9 (PHQ-9) using cut off of 10 for detecting clinical depression
- • 4. ability to read and understand Chinese
- • 5. possession of smartphone
- Exclusion Criteria:
- • 1. presence of prominent suicidality (suicide plans and suicide attempts) as determined by the Mini-International Neuropsychiatric Interview (MINI)
- • 2. a clinical diagnosis of psychosis, schizophrenia, bipolar disorders, or intellectual disability
- • 3. presence of other sleep disorders that significantly affect sleep continuity or sleep quality (e.g. restless leg symptoms or obstructive sleep apnea syndrome) as determined by validated Diagnostic Interview for Sleep Patterns and Disorders
- • 4. currently receiving psychological treatment for insomnia and/or pharmacological treatment for depression
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sha Tin, New Territories, Hong Kong
Patients applied
Trial Officials
Rachel Ngan Yin Chan, PhD
Principal Investigator
Department of Psychiatry, the Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported